Rydex Biotechnology Fund Class H (RYOAX)

81.51
Net Asset Value
-0.35%
1 Day
+3.98%
Year-to-Date
Overall Morningstar Rating
Health
Style or Category
No Load
Sales Expenses
1.61%
Expense Ratio
High
Morningstar Risk Rating™
Investment Objective The investment seeks to provide capital appreciation. Under normal circumstances- the fund invests substantially all (at least 80%) of its net assets in equity securities of Biotechnology Companies that are traded in the United States and in derivatives- which primarily consist of futures contracts and options on securities- futures contracts- and stock indices. It may invest to a significant extent in the securities of Biotechnology Companies that have small to mid-sized capitalizations. The fund is non-diversified.

Performance

1 month+0.39% 3 years+1.89%
3 months+7.30% 5 years+17.52%
1 year+20.39% Since inception+12.05%
Data through --

Peer Comparisonvs. Health

 RYOAXCategory
Performance 5-yr return+17.52%+17.28%
Expense ratio1.61%1.31%
Risk 5 year sharpe ratio0.811.11
Net assets$318.1M$3.2B
Average market cap$13.8B$9.5B
Average P/E23.722.6
Portfolio turnover207%207%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyRydex Funds
Fund manager & tenureMichael Byrum / 19 Years
Minimal initial investment$2,500.00
Minimum IRA investment$1,000.00

Holdings

U.S. stock99.73%
Fixed income0.27%
International stock0.00%
Cash0.00%
Other0.00%
Top 5 Sectors
Portfolio weighting
Healthcare 100.00%
Business service 0.00%
Consumer goods 0.00%
Consumer service 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
ABBV AbbVie6.56%
AMGN Amgen5.41%
GILD Gilead Sciences4.96%
BIIB Biogen4.01%
CELG Celgene3.90%
VRTX Vertex Pharmaceuticals Inc3.24%
SHPG Shire2.88%
REGN Regeneron Pharmaceuticals2.81%
ILMN Illumina Inc2.77%
ALXN Alexion Pharmaceuticals Inc2.46%